Science and Enterprise

Tag: merger

  • Edwards Lifesciences Acquires Blood Monitor Device Company

    Edwards Lifesciences Corp., a developer of cardiac and blood monitoring technology in Irvine, California, acquired BMEYE B.V., a maker of non-invasive blood-oxygen monitors in the Netherlands. The purchase price was €32.5 million ($42.0 million). Edwards Lifesciences designs and manufactures tissue replacement heart valves and valve repair products, as well as critical care, cardiac surgery systems,…

  • Luminex Corp. Acquires Molecular Diagnostics Developer

    Luminex Corporation, a maker of medical diagnostics technologies in Austin, Texas will acquire Hayward, California-based GenturaDx, a developer of genomic testing systems. The $50 million deal involves Luminex purchasing all outstanding shares in the privately-owned GenturaDx. Luminex develops and manufactures instruments, software, reagents, and assays used in clinical labs as well as in pharmaceutical, diagnostic,…

  • Device Maker Teleflex Acquires Biomedical Materials Company

    Teleflex Inc., a medical device provider in Limerick, Pennsylvania, has acquired Semprus BioSciences in Cambridge, Massachusetts, a developer of coatings for medical implants. The deal has an immediate value of $30 million. Teleflex is a manufacturer of medical devices for vascular access, including catheters and dialysis access products. The company also develops devices for regional…

  • Circuit Manufacturer Acquires Wireless Network Developer

    Silicon Laboratories Inc. in Austin, Texas has acquired Ember Corporation in Boston to supplement the Silicon Labs product line in low-power networking for home and business applications. The initial value of the purchase is placed at $72 million. Ember is expected to contribute $10-$12 million in revenue in the second half of 2012. Silicon Labs…

  • AstraZeneca to Acquire Biotech for $1.26 Billion

    The global pharmaceutical maker AstraZeneca says it will acquire Ardea Biosciences Inc., a biotechnology company in San Diego developing small molecule therapies. The deal is valued at $1.26 billion, with AstraZeneca paying $32.00 a share, a 54 percent premium over Ardea’s closing price on Friday 20 April. Ardea’s most advanced drug candidate is lesinurad taken…

  • Venture-Backed Exit Value Up, Numbers Down in Q1 2011

    The number of exit deals for new companies in the U.S. backed by venture capital (VC) in the first quarter of 2011 dropped, while the total value of the deals increased compared to the same period in 2010. Science-based companies figured prominently in the first-quarter deals involving VC-backed enterprises. Data on exits, where enterprises backed…

  • Sanofi-aventis Acquires Genzyme in $20.1B Deal

    Sanofi-aventis, the Paris-based pharmaceutical company, has acquired biotechnology company Genzyme Corporation in Cambridge, Massachusetts for $74.00 per share, or about $20.1 billion. The deal includes other payments to Genzyme shareholders based on net sales and developments involving specific Genzyme drugs. Genzyme is expected to add its treatments for several rare diseases to Sanofi-aventis’s current collection…

  • IPOs, Mergers for Venture-Funded Companies Gain in 2010

    The number and value of exit deals — where enterprises backed by venture capital (VC) become financially self-sustaining — increased sharply in 2010, compared to 2009.  The compilation by Dow Jones VentureSource shows 514 exit deals took place in 2010 a 25 percent increase, with those deals netting $39.3 billion, a jump of 72 percent…

  • VC Mergers/Acquisitions Rebound, IPOs Drop in Q3 2010

    The number and value of U.S. disclosed venture capital (VC) exit deals in the third quarter of 2010 showed a mixed pattern compared to the second quarter of 2010, with more mergers and acquisitions (M&As) of VC-backed properties, but somewhat fewer initial public offerings (IPOs) of company stock. Exit deals — either M&As or IPOs…

  • Merck to Cut Workforce, Close Research and Manufacturing Sites

    Merck & Co. in Whitehouse Station, New Jersey announced today a consolidation of its research and manufacturing operations, reducing its workforce 15 percent and closing eight research and eight manufacturing sites. The reductions in sites and workers are part of Merck’s integration of facilities with Schering-Plough, following its acquisition in November 2009. The company says…